Efficient Generation of Functional TCRαβ⁺ Cytotoxic T Cells from hiPSCs via Small-Molecule Modulation

Area of Science:

• Stem cell biology
• Immunology
• Molecular medicine

Background:

• Human induced pluripotent stem cells (hiPSCs) are a valuable resource for regenerative medicine and immunotherapy.
• Current methods for differentiating hiPSCs into cytotoxic T lymphocytes (CTLs) have limited efficiency.
• Optimizing T cell differentiation from hiPSCs is crucial for advancing cell-based therapies.

Purpose of the Study:

• To identify small-molecule modulators that enhance the efficiency of T cell differentiation from hiPSCs.
• To investigate the impact of these modulators on T cell maturation and cytotoxic function.
• To explore the potential of these strategies for developing improved hiPSC-derived T cell therapies.

Main Methods:

• Utilized stroma-free differentiation protocols for hiPSCs into T cells.
• Screened small-molecule compounds targeting specific developmental stages (ProT cells).
• Assessed T cell populations (CD3+, TCRαβ+, CD4+, CD8+), cytotoxicity assays, and lymphopoiesis in zebrafish models.

Main Results:

• Inhibition of AHR, DOT1L, or GSK3 significantly increased T cell maturation and CTL production (up to 2000-fold).
• hiPSC-derived T cells exhibited enhanced cytotoxic activity in assays using bispecific antibodies (AMG-701, Blinatumomab).
• AHR inhibition also promoted B lymphopoiesis, indicating shared regulatory pathways.

Conclusions:

• Small-molecule inhibition of AHR, DOT1L, or GSK3 provides a robust strategy to enhance hiPSC-derived CTL production and function.
• These findings advance the development of universal and autologous hiPSC-based T cell therapies.
• The study offers a viable path for improving cell therapies, even with patient-specific hiPSC lines.